<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134273</url>
  </required_header>
  <id_info>
    <org_study_id>CLPG 1809</org_study_id>
    <nct_id>NCT04134273</nct_id>
  </id_info>
  <brief_title>Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in&#xD;
      the treatment of acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives are to evaluate the therapeutic equivalence and safety of Taro Product&#xD;
      to RLD in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy&#xD;
      of the test and reference products over the placebo control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of Bioequivalence</measure>
    <time_frame>Week 12</time_frame>
    <description>Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1260</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CLPG Topical Gel 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin Phosphate Topical Gel 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle of the test product), applied to the face twice a day for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLPG Topical Gel 1%</intervention_name>
    <description>Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)</description>
    <arm_group_label>CLPG Topical Gel 1%</arm_group_label>
    <other_name>Topical Gel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Clindamycin Phosphate topical gel 1%</description>
    <arm_group_label>Clindamycin Phosphate Topical Gel 1%</arm_group_label>
    <other_name>Topical Gel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)</description>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis&#xD;
             of acne vulgaris&#xD;
&#xD;
          -  Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB&#xD;
             approved written informed consent. Subjects 12 to 17 years of age, inclusive, must&#xD;
             have provided IRB approved written assent; this written assent must be accompanied by&#xD;
             an IRB approved written informed consent from the Subject's legally acceptable&#xD;
             representative (i.e., parent or guardian).&#xD;
&#xD;
          -  Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3,&#xD;
             or 4 as per the Investigator's Global Assessment (IGA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study&#xD;
             participation.&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to clindamycin or lincomycin and/or any&#xD;
             ingredients in the study drugs.&#xD;
&#xD;
          -  Subjects with the presence of any skin condition that would interfere with the&#xD;
             diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis,&#xD;
             psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications,&#xD;
             steroid acne, steroid folliculitis, or bacterial folliculitis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

